Bioventures 2018 L.P. Mpm Sells 44,259 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Posted by Stanley Muller on Sep 2nd, 2026

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) major shareholder Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock in a transaction on Monday, August 31st. The stock was sold at an average price of $6.99, for a total value of $309,370.41. Following the transaction, the insider owned 4,231,434 shares in the company, valued at approximately $29,577,723.66. This represents a 1.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Bioventures 2018 L.P. Mpm also recently made the following trade(s):

On Friday, August 28th, Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.01, for a total transaction of $26,168.33.
On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.20, for a total transaction of $280,238.40.

Entrada Therapeutics Price Performance

Shares of TRDA stock opened at $7.07 on Wednesday. The company has a market capitalization of $275.31 million, a PE ratio of -1.79 and a beta of -0.25. The firm’s 50-day moving average is $7.08 and its two-hundred day moving average is $9.25. Entrada Therapeutics, Inc. has a 12 month low of $5.02 and a 12 month high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The firm had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $2.32 million. Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. Sell-side analysts forecast that Entrada Therapeutics, Inc. will post -4.03 EPS for the current year.

Hedge Funds Weigh In On Entrada Therapeutics

Several large investors have recently made changes to their positions in TRDA. Odyssean LLC acquired a new stake in Entrada Therapeutics in the 2nd quarter valued at approximately $230,000. Nantahala Capital Management LLC purchased a new stake in Entrada Therapeutics in the second quarter valued at approximately $2,212,232. Public Employees Retirement System of Ohio acquired a new position in Entrada Therapeutics during the second quarter worth $276,000. Bank of America Corp DE acquired a new position in Entrada Therapeutics during the second quarter worth $426,000. Finally, 5AM Venture Management LLC acquired a new position in Entrada Therapeutics during the second quarter worth $29,854,949. 86.39% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Roth Capital reissued a “buy” rating and set a $11.00 target price on shares of Entrada Therapeutics in a research note on Wednesday, August 12th. Guggenheim decreased their price target on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Monday, June 8th. Weiss Ratings upgraded Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Finally, HC Wainwright downgraded Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Entrada Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $17.75.

Check Out Our Latest Analysis on TRDA

Entrada Therapeutics Company Profile

(Get Free Report)

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.